An Illustration of Challenges in Respiratory Drug Development

This webinar will examine past design issues, current techniques to raise standards and new technology which will aid future understanding.

Key Discussion Points:

• Look at the importance of understanding clinical study design and the impact it has on specific patient populations.
• Show examples of how study design has generated unexpected outcomes in relation to treatment response for FEV1 and exacerbations.
• Discuss how critical Spirometry endpoints are important to many existing respiratory studies.
• Review the limitations around existing lung function endpoints of FEV1 and FVC .
• Highlight some of the factors which can be improved by active management to increase the power of studies and to improve the understanding of which patients are responsive to therapy.

Speakers

Philip Lake, PhD, Executive Director of Scientific Affairs, Respiratory, Chiltern

Philip Lake, PhD, brings nearly two decades of experience to his role as Chiltern’s executive director, bioPharmaceutical development. He has extensive respiratory development experience, covering chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis and cystic fibrosis. Dr. Lake’s vast expertise also includes dual and triple combination development, anti-inflammatories, monoclonal antibodies and anti-infectives, anti-fibrotics and CFTR potentiators. He has held senior-level positions for several leading Pharmaceutical and clinical research organizations including Senior Manager and Clinical Program Head at GlaxoSmithKline and executive director, respiratory project management at Covance. Dr Lake has worked extensively on refining a high quality low variability approach to achieving optimal research grade spirometry data.

Message Presenter

Jan De Backer, PhD, CEO, Fluidda

Jan De Backer, PhD, has received many awards for his research in respiratory medicine. He founded Fluidda in 2005 and has held the position as CEO for nine years.

Message Presenter